Anzeige
Mehr »
Samstag, 20.09.2025 - Börsentäglich über 12.000 News
Der nächste Gold-Gigant Afrikas? Avanti Gold steigt um 1.500% - und steht womöglich erst am Anfang
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EQV9 | ISIN: US68235C2061 | Ticker-Symbol: 7OC0
NASDAQ
19.09.25 | 21:59
3,460 US-Dollar
+2,67 % +0,090
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
INSIGHT MOLECULAR DIAGNOSTICS INC Chart 1 Jahr
5-Tage-Chart
INSIGHT MOLECULAR DIAGNOSTICS INC 5-Tage-Chart

Aktuelle News zur INSIGHT MOLECULAR DIAGNOSTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
INSIGHT MOLECULAR DIAGNOSTICS Aktie jetzt für 0€ handeln
FrInsight Molecular Diagnostics Inc. - 8-K, Current Report1
08.09.iMDx launches 5,000-patient registry to study transplant rejection test1
08.09.Insight Molecular Diagnostics Inc.: Insight Molecular Diagnostics Announces Positive Strategic Update and Novel Registry Database1075,000-participant, multi-center registry supported by iMDx's central lab and transplant center partnersNew hospital-based data seeks to further differentiate pending kitted assay that measures biomarker...
► Artikel lesen
08.09.Insight Molecular Diagnostics Inc.: IMDX Enrolls First Patient in GraftAssureDx Clinical Trial and Welcomes New Hospital Participants95iMDx's ClinicalTrials.gov listing now names 10 leading transplant centers, up from 5 previouslyGraftAssureDx remains on track for FDA submission by end of 2025, commercial launch in 2026 NASHVILLE...
► Artikel lesen
18.08.Insight Molecular Diagnostics Inc. - S-8, Securities to be offered to employees in employee benefit plans1
12.08.Needham bestätigt Kaufempfehlung für Insight Molecular Diagnostics1
11.08.OncoCyte GAAP EPS of -$0.301
11.08.Insight Molecular Diagnostics Inc. - 10-Q, Quarterly Report1
11.08.Insight Molecular Diagnostics Inc.: IMDX Reports Q2 2025 Results and Momentum Toward GraftAssureDx Launch606Reiterating timelines for FDA submission in 2025Transplant clinical trial has attracted leading transplant hospitalsBooked first revenue from first-generation GraftAssureIQ research-use-only kits...
► Artikel lesen
11.08.Insight Molecular Diagnostics Inc. - 8-K, Current Report3
08.08.Exploring Insight Molecular's Earnings Expectations1
28.07.Insight Molecular Diagnostics Inc.: iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 20253
02.07.Insight Molecular Diagnostics Inc. - 8-K, Current Report2
23.06.iMDx transplant test shows equivalence to commercial alternatives2
23.06.Insight Molecular Diagnostics Inc.: iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing3
17.06.Oncocyte changes name to Insight Molecular Diagnostics and moves headquarters to Nashville4
17.06.Oncocyte Corp - 8-K, Current Report1
17.06.Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville1.540New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology careiMDx sponsoring GraftAssureIQ research-use-only kits at transplant labs globallyExhibiting...
► Artikel lesen
19.05.Oncocyte Corporation: Medicare Boosts Reimbursement for Oncocyte's Flagship Technology167New price of $2,753 for the GraftAssureCore assay increases total addressable market size and margin opportunityBrings pricing in line with existing competitive technologyExpands market appeal for...
► Artikel lesen
13.05.Needham maintains Buy on OncoCyte, price target at $4.251
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1